NewAmsterdam Pharma Company NV - Warrants (15/11/2027)
NAMSW
Get informed when a big investor buys or sells
+ FollowMarket Cap$3.82B
Close$
$2.92
84.6% downside
Current Fair Value
84.6% downsideOvervalued by 84.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.82 Billion |
|---|---|
| Enterprise Value | $3.36 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.75 |
| Beta | 0.08 |
| Outstanding Shares | 121,102,500 |
Return
| Return on Equity | -31.98% |
|---|---|
| Return on Assets | -29.04% |
| Return on Invested Capital | -34.88% |
Valuation & Multiples
| P/E Ratio | -17.5 |
|---|---|
| PEG | -77.61 |
| Price to Sales | - |
| Price to Book Ratio | 3.8 |
| Enterprise Value to Revenue | 149.01 |
| Enterprise Value to EBIT | -14.49 |
| Enterprise Value to Net Income | -16 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 7, 2026
EPS Estimate
$-0.46
Average shareholder expectationRevenue Estimate
$1.74 M
Average shareholder expectationNext Earnings Call
Expected Date
August 12, 2026
EPS Estimate
$-0.47
Average shareholder expectationRevenue Estimate
$1.88 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data